BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9834823)

  • 21. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Thödtmann F; Theiss F; Kemmerich M; Heinrich B; Laubenbacher C; Quasthoff S; Kau R; Herzog M; Diergarten K; Hanauske AR
    Ann Oncol; 1998 Mar; 9(3):335-7. PubMed ID: 9602270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
    Caponigro F; Massa E; Manzione L; Rosati G; Biglietto M; De Lucia L; Sguotti C; Sganga P; Avallone A; Comella P; Mantovani G; Comella G
    Ann Oncol; 2001 Feb; 12(2):199-202. PubMed ID: 11300324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
    J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results.
    Airoldi M; Cattel L; Marchionatti S; Recalenda V; Pedani F; Tagini V; Bumma C; Beatrice F; Succo G; Maria Gabriele A
    Am J Clin Oncol; 2003 Aug; 26(4):378-81. PubMed ID: 12902890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results.
    Airoldi M; Cattel L; Cortesina G; Giordano C; Passera R; Pedani F; Novello S; Bumma C; Gabriele P
    Anticancer Res; 2003; 23(3C):2845-52. PubMed ID: 12926122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.
    Clark JI; Hofmeister C; Choudhury A; Matz G; Collins S; Bastian R; Melian E; Emami B; Petruzzelli G
    Cancer; 2001 Nov; 92(9):2334-40. PubMed ID: 11745288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
    Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
    Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.
    Conroy T; Etienne PL; Adenis A; Ducreux M; Paillot B; Oliveira J; Seitz JF; Francois E; Van Cutsem E; Wagener DJ; Kohser F; Daamen S; Praet M; Gorlia T; Baron B; Wils J;
    Ann Oncol; 2002 May; 13(5):721-9. PubMed ID: 12075740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
    Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
    Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
    Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
    Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Specenier P; Rasschaert M; Vroman P; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Am J Clin Oncol; 2011 Oct; 34(5):472-7. PubMed ID: 20938321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
    J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.
    Wang TF; Chu SC; Kao RH; Yao CY; Li CC
    Jpn J Clin Oncol; 2008 Jul; 38(7):459-63. PubMed ID: 18586668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Espinosa E; Zamora P; Millá A; Morales S; Molina R; Mira M; González Barón M;
    Head Neck; 2002 Dec; 24(12):1054-9. PubMed ID: 12454943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
    Duffaud F; Borner M; Chollet P; Vermorken JB; Bloch J; Degardin M; Rolland F; Dittrich C; Baron B; Lacombe D; Fumoleau P;
    Eur J Cancer; 2004 Dec; 40(18):2748-52. PubMed ID: 15571957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
    Recchia F; Lalli A; Lombardo M; De Filippis S; Saggio G; Fabbri F; Rosselli M; Capomolla E; Rea S
    Cancer; 2001 Aug; 92(4):814-21. PubMed ID: 11550152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.